Boston, MA 05/27/2014 (wallstreetpr) – Neuralstem, Inc. (NYSEMKT:CUR), the producer of neural stem cells with its patented technology, will be announcing data from the NSI-189 study in major depressive disorder at the Annual Meeting of the American Society of Clinical Psychopharmacology, which is to be held in Hollywood, Florida next month.
The study on MDD is currently in Phase 1b and employs the company’s first in class, lead neurogenic small molecule compound, the NSI-189. During pre- clinical studies, the compound demonstrated abilities to enhance the formation of new neurons in animals, through a process called neurogenesis. In humans, this compound, NSI-189 Phosphate promotes the formation of hippocampus, which are derived stem cells of the brain and spinal cord. The results of the randomized, placebo controlled, double blind, multi dosage escalation study in the Phase lb will be announced in the annual meeting which is scheduled to be held on June 17, 2014.
New Treatment
The study was authored by the MD, Medical Director of Clinical Trials Network and Institute, Massachusetts General Hospital, Marlene Freeman. He is also an Associate Professor of Psychiatry at the Harvard Medical School and will be discussing the results of the trail. Additionally, the trail results also show that depressed patients who were subjected to two different dosage levels demonstrated clinically significant decline in cognitive and depressive symptoms across all actions against placebo. What is more profound is that the results were seen to be persistent for the entire follow up duration.
In accordance with the trial outcome, investigators such as the MD, Executive Vice Chair, Department of Psychiatry, Maurizio Fava, MD, Executive Vice Chair, Department of Psychiatry, who is also a lead author of the study established that a neurogenesis based research could lead to the development of new methods of treatments for various depressive disorders. Fava is also the Executive Director of Clinical Trials Network and Institute at the Massachusetts General Hospital.
